Eric Nuermberger

Medicine & Life Sciences

1. Tuberculosis 100%
2. rifapentine 53%
3. Pyrazinamide 45%
4. Mycobacterium tuberculosis 41%
5. Rifampin 41%
6. bedaquiline 39%
7. pretomanid 37%
8. Moxifloxacin 36%
9. Pharmaceutical Preparations 34%
10. Isoniazid 31%
11. Multidrug-Resistant Tuberculosis 28%
12. Mycobacterium ulcerans 27%
13. Buruli Ulcer 23%
14. Linezolid 23%
15. Clofazimine 20%
16. Pharmacokinetics 16%
17. Mycobacterium abscessus 16%
18. Therapeutics 15%
19. PNU-100480 15%
20. Latent Tuberculosis 13%
21. Lung 12%
22. rifamycin SV 11%
23. Aerosols 11%
24. Anti-Bacterial Agents 11%
25. Lactams 10%
26. Duration of Therapy 10%
27. Oxazolidinones 10%
28. Infections 9%
29. Guinea Pigs 9%
30. Streptomycin 9%
31. In Vitro Techniques 9%
32. OPC-67683 9%
33. 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl) imidazo(1,2-a)pyridine-3-carboxamide 9%
34. Animal Models 8%
35. pyrazinoic acid 8%
36. Pulmonary Tuberculosis 8%
37. Meropenem 8%
38. Rifamycins 7%
39. Recurrence 7%
40. Extensively Drug-Resistant Tuberculosis 7%
41. Clinical Trials 6%
42. Drug Combinations 6%
43. Clarithromycin 6%
44. Granuloma 6%
45. Drug Development 6%
46. Fluoroquinolones 5%
47. Nitroimidazoles 5%
48. Drug Therapy 5%
49. mycolactone 5%